Seminars in Oncology
Volume 33 , Pages 24-28 , June 2006

Use of Pemetrexed in Breast Cancer

  • Christian Dittrich

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Prof Christian Dittrich, Ludwig Boltzmann-Institute for Applied Cancer Research, 3rd Medical Department - Center for Oncology and Hematology, Kaiser Franz Josef-Spital, Kundratstrasse 3, A-1100 Vienna, Austria.

References 

  1. Shih C , Grindey GB , Barnett CJ , et al.   Structure-activity relationship studies of novel pyrrolopyrimidine antifolate LY231514 . Proc Am Assoc Cancer Res . 1992;33:411; abstr
  2. Shih C , Gossett L , Gates S , et al.   LY231514 and its polyglutamates exhibit potent inhibition against both human dihydrofolate reductase (DHFR) and thymidylate synthase (TS) (Multiple folate enzymes inhibition) . Ann Oncol . 1996;7(suppl 1):85; abstr
  3. Grindey GB , Shih C , Barnett CJ , et al.   LY231514 (A novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS)) . Proc Am Assoc Cancer Res . 1992;33:411; abstr
  4. Hanauske AR , Chen V , Paoletti P , et al.   Pemetrexed disodium (A novel antifolate clinically active against multiple solid tumors) . Oncologist . 2001;6:363–373
  5. Niyikiza C , Baker S , Johnson R , et al.   MTA (LY231514) (Relationship of vitamin metabolite profile, drug exposure, and other patient characteristics to toxicity) . Ann Oncol . 1998;9(suppl 4):126; abstr
  6. Niyikiza C , Hanauske AR , Rusthoven JJ , et al.   Pemetrexed safety and dosing strategy . Semin Oncol . 2002;29(suppl 18):24–29
  7. Vogelzang NJ , Rusthoven JJ , Symanowski J , et al.   Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma . J Clin Oncol . 2003;21:2636–2644
  8. Eli Lilly and Company. Clinical Investigator Brochure for LY231514 . Indianapolis, IN: Eli Lilly and Company; 2004; February
  9. Gomez HL , Santillana S , Vallejos C , et al.   A phase II trial of pemetrexed in advanced breast cancer (Clinical response and association with molecular target expression) . Clin Cancer Res . 2006;12:832–838
  10. O’Shaughnessy JA , Clark RS , Blum JL , et al.   Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane and capecitabine for advanced breast cancer . Clin Breast Cancer . 2005;6:743–749
  11. International Union Against Cancer . In:  Sobin LH ,  Wittekind CH editor. TNM Classification of Malignant Tumours . New York, NY: Wiley-Liss Inc; 2002;
  12. Miles DW , Smith IE , Coleman RE , et al.   A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer . Eur J Cancer . 2001;37:1366–1371
  13. Martin M , Spielmann M , Namer M , et al.   Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines . Ann Oncol . 2003;14:1246–1252
  14. Spielmann M , Martin M , Namer M , et al.   Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane (An interim analysis) . Clin Breast Cancer . 2001;2:47–51
  15. Llombart-Cussac A , Theodoulou M , Rowland K , et al.   A phase II trial of pemetrexed disodium (ALIMTA, LY231514, MTA) in metastatic breast cancer (MBC) patients who have failed anthracyclines (A) and taxanes (T) (salvage chemotherapy) . Breast Cancer Res Treat . 2000;64:122; abstr
  16. Teicher BA , Chen U , Shih C , et al.   Treatment regimen including the multitargeted antifolate LY231514 in human tumor xenografts . Clin Cancer Res . 2000;6:1016–1023
  17. Hughes AN , Lind M , Azzabi A , et al.   A phase I dose escalation study of doxorubicin in combination with pemetrexed (Alimta), multitargeted antifolate . Breast Cancer Res Treat . 2001;69:286; abstr
  18. Paridaens R , Dirix R , Mellaerts N , et al.   Phase I study of pemetrexed (ALIMTA) and epirubicin in patients with locally advanced or metastatic breast cancer . Breast Cancer Res Treat . 2003;79:280; abstr
  19. Dittrich C , Petruzelka L , Vodvarka P , et al.   Pemetrexed and cyclophosphamide in patients with locally advanced or metastatic breast cancer (A phase I study) . Proc Am Soc Clin Oncol . 2003;22:40; abstr
  20. Nakagawa K , Kudoh S , Matsui K , et al.   A phase I study of pemetrexed supplemented with folic acid (FA) and vitamin B12 (VB12) in Japanese patients with solid tumors . Eur J Cancer . 2004;2(suppl):148; abstr
  21. Ma CX , Steen P , Rowland KM , et al.   A phase II study of a combination of pemetrexed (Pem) and gemcitabine (Gem) in patients with metastatic breast cancer (MBC) (An NCCTG study) . J Clin Oncol . 2004;22(suppl):14S; abstr
  22. Adjei AA , Erlichmann C , Sloan JA , et al.   Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors . J Clin Oncol . 2000;18:1748–1757
  23. Kolaric K , Vukas D . Carboplatin activity in untreated metastatic breast cancer patients-Results of a phase II study . Cancer Chemother Pharmacol . 1991;27:409–412
  24. O’Brien ME , Talbot DC , Smith IE . Carboplatin in the treatment of advanced breast cancer (A phase II study using a pharmacokinetically guided dose schedule) . J Clin Oncol . 1993;11:2112–2117
  25. Garin A , Manikhas M , Biakhov M , et al.   A phase II study of pemetrexed plus carboplatin as first-line therapy of patients with locally advanced (LA) or metastatic breast cancer (MBC) (Preliminary results) . J Clin Oncol . 2005;23(suppl):51S; abstr

 Dr Dittrich has received honoraria from Eli Lilly and Company.

PII: S0093-7754(06)00137-0

doi: 10.1053/j.seminoncol.2006.03.017

Seminars in Oncology
Volume 33 , Pages 24-28 , June 2006

Article Tools